August 22, 2024

Reaction to MHRA decision and NICE draft guidance on lecanemab // NICE explainer of the guidance & Q&A

With the announcement on 22nd August 2024 from the MHRA and NICE on lecanemab for Alzheimer’s Disease, journalists heard from the UK’s leading dementia research organisations as they reacted to the news and spoke to what this means for research and treatment of dementia in the UK.

Speakers included:

Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society

Prof Tara Spires-Jones,  Group Leader in the UK Dementia Research Institute, and Director of the Centre for Discovery Brain Sciences at the University of Edinburgh

David Thomas, Head of Policy, at Alzheimer’s Research UK

Experts from NICE were also on the call to answer journalists’ questions about the draft guidance issued.

Speakers included:

Professor Jonathan Benger, Chief Medical Officer, NICE

Helen Knight, Director of Medicines Evaluation, NICE